Chemical & Biomedical Imaging · 2023 · 15 citations · 35 references
MedicinePathologyRadiologyBiomedical ImagingDiagnostic ImagingDiagnostic RadiologyContrast AgentsFibrosisInterstitial Lung Disease ImagingMagnetic Resonance ImagingPulmonary ImagingTargeted Imaging AgentsFibrosis QuantificationIdiopathic Pulmonary Fibrosis ImagingLung DiseasesLung FibrosisMolecular Contrast AgentsProtein-based Imaging AgentsPulmonary Fibrosis ProgressionTargeted Contrast Agents
High Resolution Image Download MS PowerPoint Slide Chronic lung diseases, such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), are major leading causes of death worldwide and are generally associated with poor prognoses. The heterogeneous distribution of collagen, mainly type I collagen associated with excessive collagen deposition, plays a pivotal role in the progressive remodeling of the lung parenchyma to chronic exertional dyspnea for both IPF and COPD. To address the pressing need for noninvasive early diagnosis and drug treatment monitoring of pulmonary fibrosis, we report the development of human collagen-targeted protein MRI contrast agent (hProCA32.collagen) to specifically bind to collagen I overexpressed in multiple lung diseases. When compared to clinically approved Gd 3+ contrast agents, hProCA32.collagen exhibits significantly better r 1 and r 2 relaxivity values, strong metal binding affinity and selectivity, and transmetalation resistance. Here, we report the robust detection of early and late-stage lung fibrosis with stage-dependent MRI signal-to-noise ratio (SNR) increase, with good sensitivity and specificity, using a progressive bleomycin-induced IPF mouse model. Spatial heterogeneous mapping of usual interstitial pneumonia (UIP) patterns with key features closely mimicking human IPF, including cystic clustering, honeycombing, and traction bronchiectasis, were noninvasively detected by multiple MR imaging techniques and verified by histological correlation. We further report the detection of fibrosis in the lung airway of an electronic cigarette-induced COPD mouse model, using hProCA32.collagen-enabled precision MRI (pMRI), and validated by histological analysis. The developed hProCA32.collagen is expected to have strong translational potential for the noninvasive detection and staging of lung diseases, and facilitating effective treatment to halt further chronic lung disease progression.
35
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi, Roland M. du Bois, Ganesh Raghu et al. · New England Journal of Medicine · 2014 · 4.6K citations · Full text
William D. Travis, Ulrich Costabel, David M. Hansell et al. · American Journal of Respiratory and Critical Care Medicine · 2013 · 4.3K citations · Full text
Standardized Quantification of Pulmonary Fibrosis in Histological Samples
Ralf‐Harto Hübner, Wolfram Gitter, Nour Eddine El Mokhtari et al. · BioTechniques · 2008 · 829 citations · Full text
Medicine, Pathobiology, Pathology +15